Research Spotlight: The Public Health Impact of the FDA’s Request for Additional Safety Data on Cytisine for Tobacco Cessation
Cytisine, a plant-based medication, has been used to treat tobacco dependence for decades in other countries.
NewsJul | 19 | 2022
Pediatricians have seen firsthand their patients struggle with nicotine addiction due to e-cigarette use and are now calling on the U.S. Food and Drug Administration to take strong action to curb youth use of these addictive products. A white paper led by Jonathan Winickoff, MD, MPH, pediatrician at Mass General for Children and director of Pediatric Research at the Massachusetts General Hospital Tobacco Research & Treatment Center, and endorsed by pediatricians and pediatric tobacco control experts from across the nation summarizes the serious, continued threat flavored tobacco products cause to youth and describes the deliberate product design and marketing tactics used by e-cigarette companies to make their products more appealing to children and adolescents.
Swift action is needed to address e-cigarette use among young people. Winickoff and his co-authors here offer critical recommendations, including marketing restrictions and flavored tobacco product bans, that have been endorsed by more than 200 U.S. pediatricians to protect children from the dangers of e-cigarettes.
Cytisine, a plant-based medication, has been used to treat tobacco dependence for decades in other countries.
Researchers found that smoking decreases the life expectancy of people with HIV on antiretroviral therapy in South Africa by three to six years, of which two to five years could be regained by smoking cessation.
A plant-based medication called cytisinicline may be an effective therapy to help them stop vaping, according to the results of a new clinical trial co-led by an investigator from Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system.
Nancy Rigotti, MD, director of the Tobacco Research and Treatment Center at Massachusetts General Hospital, shares tips for how to quit smoking for once and for all.
A Phase 3 clinical trial has demonstrated the safety and effectiveness of cytisinicline, a smoking cessation medication which, if approved by regulatory authorities, would become the first such product approved in this country in nearly 20 years.
During three months of treatment for smoking cessation following hospital discharge, a healthcare system-based model using proven medications and counseling calls achieved better quit rates for adults who smoked than referral to a state telephone quitline.